Hansa Biopharma: Increase of the number of shares and votes
Lund, Sweden, December 30, 2022. Hansa Biopharma AB “Hansa” or the “Company”, (Nasdaq Stockholm: HNSA), a pioneer in enzyme technology for rare immunological conditions, today announces that the Company’s registered share capital and number of outstanding shares and votes have increased during the month of December 2022 as a result of the directed share issue announced on December 13, 2022. Through the directed share issue, 7,848,111 new ordinary shares were issued and the share capital increased by SEK 7,848,111. As of today, the total number of registered shares of the Company amounts